Using Artificial Intelligence to Detect Cancer

Cancer has long been a major issue across all of society. A lot of work has been done to help stop them, but the medical industry still a long way off …

Artificial Intelligence to detect cancer

Artificial Intelligence to detect cancerArtificial Intelligence to detect cancerArtificial Intelligence to detect cancer

Cancer has long been a major issue across all of society. A lot of work has been done to help stop them, but the medical industry still a long way off perfect. Based on cancer statistics in the United States, 38.4% of men and women will get cancer at some point in their life. Detecting this cancer early is the best way to ensure proper treatment can be given.

Using Artificial intelligence to detect cancer and other major illnesses has been gradually improving over time. Scientists have already had success with AI detecting cancer in patients. Further, AI has been used to analyse brain scans and detect brain tumours among other neurological disorders.

Cancer Detection:

With the apparent rise in cancer cases around in the US alone, there is a need for technology to help detect these cancers early, and before they do any real damage. Thankfully, with the advancement of technology and medicine over the last 50 years, there has already been much improvement in this field. However, there were still a large number of cases that went undetected too long.

To help improve the detection rate of cancers, scientists began using Artificial Intelligence to analyse scans and other patient data. One study in 2015 showed that using Artificial Intelligence to cancer resulted in a 96.3 percent accuracy. The test was conducted in turkey using new patients data from the east side of the country.

Using artificial intelligence to detect cancer will only get better over time. With each new case, the AI is able to further train itself and get better. AI’s use in the medical industry will almost certainly be irreplaceable in the coming years.

Tumour Detection:

China recently conducted tests in which an artificial intelligence was able to achieve a better detection rate of brain tumours than some of their top doctors. The AI had an 80 percent detection rate, a huge improvement compared to the 63 percent higher than human doctors achieved. This wasn’t due to a lack of effort. It was reported that the doctors achieved a higher than average detection rate. This just goes to show how powerful this AI can be.

The AI was given tens of thousands of images to learn from and is able to detect a number of brain diseases. This includes meningioma and glioma and is able to do so with over a 90% detection rate.

Conclusion:

With AI being tested in many fields of medicine, there is much hope that the death rate from deadly illnesses such as cancer will be drastically reduced. There have been some great results in AI’s ability to detect this illness, often beating real doctors.

Like this:

LikeLoading…

Related Posts:

  • No Related Posts

SAP develops blockchain-based software that tracks authenticity of drugs

Looking at the above case, it’s not too much to say that blockchain not only can improve people’s lives, it can actually save people’s lives.

Multinational software company, SAP reveals to the public the major project they’re currently doing, which utilizes the distributed ledger technology, as reported by The Next Web.

According to the official release of the World Health Organization (WHO) in 2017, around 10% of medical products circulating in low and middle income countries were either fake or substandard.

In the US alone, drug wholesalers see around $7 billion worth of returned drugs, which usually being resold by to the public, regardless of their “conditions”.

With a new regulation from the US Drug Supply Chain Security Act (DSCSA), all wholesalers are now obliged to verify returned prescription drugs prior to resale.

This is where SAP’s new software has major role as it allows wholesalers to authenticate the drugs returned by pharmacies and hospitals using the blockchain-backed supply chain tracking system.

Another fact worth mentioning is the software was developed in cooperation with major pharmaceutical companies, such as Boehringer Ingelheim, GlaxoSmithKline and Merck Sharp & Dohme.

Looking at the above case, it’s not too much to say that blockchain not only can improve people’s lives, it can actually save people’s lives.

Follow Chepicap now on Twitter, YouTube, Telegram and Facebook!

Related Posts:

  • No Related Posts

Medical Marijuana Market 2019-2024: Dealers, Suppliers, Brand Strategy Demand, Pricing …

Aphria Incorporation, The Peace Naturals Project, Aurora Cannabis Inc, Canopy Growth Corporation, CANNABIS SATIVA, INC., Green Relief Inc., GW …

Medical Marijuana

Global Medical Marijuana Market report speaks the principal concerns of this market, and it also gives the detailed forecast of the market. Typically segmented by manufactures, product categories, end-users and covers geographical regions. This Report covers the past as well as future market trends of Medical Marijuana Market. The report showcases the business strategists, Market Growth Prospects & futuristic cost and revenue over the coming years. It shows Market Segmentation, Medical Marijuana Price during the Forecast period of five years. Medical Marijuana Market report also gives an In-depth analysis of major manufactures by analyzing Production and Sales Market Comparison.

This report also presents the manufacturers landscape and a corresponding detailed analysis of the major manufacturers operating in the Medical Marijuana industry. Medical Marijuana market also provides Limitations, Opportunities, and Drivers and Industry Barriers and New Entrants SWOT Analysis (Emerging Countries of Medical Marijuana, Growing Market of Medical Marijuana) which shows market condition, to get a full detailed list, view our report.

Request Sample Report of Medical Marijuana Market at http://industryresearch.co/enquiry/request-sample/13652575

Competitive Landscape

The report then estimates 2019-2024 market development trends of Medical Marijuana market. Analysis of upstream raw materials, Production Process Analysis, and Industry Chain Analysis are also carried out. In the end, the report makes some important proposals for a new project of Medical Marijuana market before evaluating its feasibility.

Medical Marijuana Market by Top Manufacturers:

Aphria Incorporation, The Peace Naturals Project, Aurora Cannabis Inc, Canopy Growth Corporation, CANNABIS SATIVA, INC., Green Relief Inc., GW PHARMACEUTICALS PLC, Insys Therapeutics, Inc., Medical Marijuana, Inc., MedReleaf Corporation

By Product Type

Dried Form, Extract Form

By Application

Pain management, Seizures, Others

By Distribution Channel

Retail Pharmacy, E-Commerce

Have Any Query? Ask Our Experts at http://industryresearch.co/enquiry/pre-order-enquiry/13652575

In the additional section, The Global Medical Marijuana Market report includes market segmentation study over the significant geographies of the universe such as North America, Asia-Pacific, Europe, South America, The Middle East & Africa and rest of the world.

TOC of Medical Marijuana Market Report Contains: –

  • Industry Overview
  • Production Market Analysis
  • Sales Market Analysis
  • Consumption Market Analysis
  • Production, Sales and Consumption Market Comparison Analysis
  • Major Manufacturers Production and Sales Market Comparison Analysis
  • Major Type of Medical Marijuana Analysis
  • Major Organization Size Analysis
  • Industry Chain Analysis
  • Global and Regional Market Forecast
  • Major Manufacturers Analysis
  • New Project Investment Feasibility Analysis

And More…

Price of Report $ 3500 (Single User Licence)

Purchase Medical Marijuana Market Report at http://industryresearch.co/purchase/13652575

Related Posts:

  • No Related Posts

Aurora Cannabis Inchares (NYSE:ACB) Shorts Increased By 24.13%

It was noted an increase on Aurora Cannabis Inchares (NYSE:ACB)’s shorted shares with 24.13%. FINRA issued in January ACB’s total 90.26 million …

It was noted an increase on Aurora Cannabis Inchares (NYSE:ACB)’s shorted shares with 24.13%. FINRA issued in January ACB’s total 90.26 million shorted shares. The up change of 24.13% from 72.71M shares was reported. With Average volume 17.38M, ACB’s former position will take 5 days to restore.

ACB is reaching $6.44 during the last trading session, after decreased 1.98%.Aurora Cannabis Inc. has 39.33M shares volume, 131.97% up from normal. ACB is uptrending and has moved 14.37% since January 19, 2018. ACB outperformed by 14.37% the S&P 500.

Aurora Cannabis Inc. produces and distributes medical cannabis products.The company has $6.43 billion market cap. It is vertically integrated and horizontally diversified across various divisions of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.29.81 is the P/E ratio. The company’s products consist of dried cannabis and cannabis oil; CanniMed vegan capsules; and hemp products, as well as sells vaporizers, consumable vaporizer accessories, and herb mills for using herbal cannabis products.

For more Aurora Cannabis Inc. (NYSE:ACB) news brought out briefly go to: Midasletter.com, Fool.com, Fool.com, Fool.com or Benzinga.com. The titles are as follows: “Aurora Cannabis Inc (TSE:ACB | NYSE:ACB) “Highest Revenue Industry Has Ever Seen” – Midas Letter” brought out on November 23, 2018, “4 Marijuana Stocks to Absolutely not Buy in 2019 – The Motley Fool” on January 04, 2019, “It’s Official: Aphria Is Trading on the NYSE — but, Is It a Buy? – The Motley Fool” with a publish date: November 03, 2018, “Does This Marijuana Stock’s Decision to List on the NYSE Make It a Buy? – Motley Fool” and the last “How Former Mexican President Vicente Fox, Khiron Life Sciences Are Building A Latin American Cannabis Juggernaut – Benzinga” with publication date: January 14, 2019.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Brookside Capital Management LLC Increased Stake in Novartis AG (NVS) as Shares Rose

… ‘Phased’ Launch Of Symjepi – Seeking Alpha” announced on January 18, 2019, “Will Aurora Cannabis Be Next to Secure a Big Partnership?

Novartis AG (NYSE:NVS) Corporate Logo

Brookside Capital Management Llc rose its stake by 56839.78% in Novartis A G (NVS), according to 2018Q3 SEC filling. The company’s stock popped up 5.30% while Brookside Capital Management Llc bought 867,375 shares. At the end of 2018Q3, the 868,901 shares of the major pharmaceuticals company held by the hedge fund were priced at $74.87 million, up from 1,526 at the end of the previous reported quarter. $207.14 billion is Novartis A G’s market cap. NVS reached $88.99 during the last trading session after $0.36 change.Novartis AG has volume of 2.75 million shares. Since January 19, 2018 NVS has risen 4.85% and is uptrending. NVS outperformed by 4.85% the S&P 500.

Brookside Capital Management Llc manages about $1.42 billion US Long portfolio. It reduced its stake in Fortive Corp by 205,463 shares to 91,036 shares, valued at $7.67M in 2018Q3, according to the filing. For a total of 905,460 shares it reduced its holding in New York Times Co (NYSE:NYT) by 614,961 shares in the quarter, and has cut its stake in Honeywell Intl Inc (NYSE:HON).

For more Novartis AG (NYSE:NVS) news announced recently go to: Seekingalpha.com, Investorplace.com, Seekingalpha.com, Finance.Yahoo.com or Seekingalpha.com. The titles are as follows: “Patience Will Be Required For Sandoz And Adamis’ ‘Phased’ Launch Of Symjepi – Seeking Alpha” announced on January 18, 2019, “Will Aurora Cannabis Be Next to Secure a Big Partnership? – Investorplace.com” on December 21, 2018, “Novartis bids for CAR-T maker CellforCure – Seeking Alpha” with a publish date: December 20, 2018, “The Daily Biotech Pulse: FDA Panel Backs Amgen’s Hypertension Drug, Adamis Allergy Drug Launched In US – Yahoo Finance” and the last “FDA to “take action” against branded drug makers using scare tactics to thwart biosimilar competition – Seeking Alpha” with publication date: January 10, 2019.

Novartis AG (NYSE:NVS) Ratings Coverage

In total 5 analysts cover Novartis (NYSE:NVS). “Buy” rating has 5, “Sell” are 0, while 0 are “Hold”. (NYSE:NVS) has 100% bullish analysts. With $105 highest and $100 lowest price target, Novartis has $93.24 average price target or 4.78% above the current ($88.99) price. 5 are the (NYSE:NVS)’s ratings reports on 19 Jan 2019 according to StockzIntelligence Inc. On Monday, November 26 Cowen & Co upgraded the shares of NVS in report to “Outperform” rating. On Monday, November 19 the stock of Novartis AG (NYSE:NVS) earned “Conviction Buy” rating by Goldman Sachs. On Tuesday, December 11 the stock has “Buy” rating by Jefferies. On Tuesday, September 11 the firm earned “Buy” rating by Citigroup. In Monday, September 10 report Bank of America upgraded the stock to “Buy” rating.

Novartis AG (NYSE:NVS) Analyst Ratings Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts